Back to mobile site

Cyclacel Pharma (CYCC) Tops Q4 EPS by 6c

March 24, 2015 4:18 PM EDT

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.20), $0.06 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $299 thousand, versus $247 thousand reported last year.

Cyclacel reported Q413 loss of $0.21 per share.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings